ArticleEuropean radiology2022
Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients.
Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Quantitative Consistency of Amide Proton Transfer-Weighted MRI for Brain Tumor Differentiation: Systematic Review of Clinical Evidence.Tomography (Ann Arbor, Mich.) · 2026Pooled it
- Fluid Suppression Techniques Combined With Amide Proton Transfer-Weighted Imaging for the Evaluation of Adult-Type Diffuse Gliomas.Korean journal of radiology · 2026Article
- Robust Extrapolated Semi-Solid Magnetization Transfer Reference Fitting for Quantitative Amide Proton Transfer Imaging at 3 T: Application to Patients With Mild Cognitive Impairment and Mild Dementia.Magnetic resonance in medicine · 2026Article
- Prediction of MGMT promoter methylation in glioblastoma and grade 4 astrocytoma using fluid-suppressed chemical exchange saturation transfer MRI and machine learning-based segmentation.Frontiers in oncology · 2026Article
- MixBranchNet: a task-adaptive network for glioma segmentation and genotype prediction by exploiting spatial-spectral correlations in CEST MRI.Frontiers in oncology · 2026Article
- Insights Into CEST Contrast at 2 ppm in Enhancing and Nonenhancing Lesions From Glioma Patients Scanned at 7 T.NMR in biomedicine · 2025Article
- Diagnostic performance of amide proton transfer-weighted imaging and four advanced diffusion-weighted MRI models for meningioma grading and subtyping.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Predicting IDH and 1p/19q molecular status of gliomas with multi-b values DWI.Frontiers in oncology · 2025Article
- Multi-pool chemical exchange saturation transfer MRI in glioma grading, molecular subtyping and evaluating tumor proliferation.Journal of neuro-oncology · 2024Article
- Utilizing the amide proton transfer technique to characterize diffuse gliomas based on the WHO 2021 classification of CNS tumors.The neuroradiology journal · 2024Article
- Amide proton transfer weighted and diffusion weighted imaging based radiomics classification algorithm for predicting 1p/19q co-deletion status in low grade gliomas.BMC medical imaging · 2024Article
- Radiomic feature reliability of amide proton transfer-weighted MR images acquired with compressed sensing at 3T.International journal of imaging systems and technology · 2024Article
- Advances in diffuse glioma assessment: preoperative and postoperative applications of chemical exchange saturation transfer.Frontiers in neuroscience · 2024Review
- Multipool-CEST and CEST-based pH assessment as predictive tools for glioma grading, IDH mutation, 1p/19q codeletion, and MGMT promoter methylation in gliomas.Frontiers in oncology · 2024Article
- Noninvasive Characterization of Metabolic Changes in Ischemic Stroke Using Z-spectrum-fitted Multiparametric Chemical Exchange Saturation Transfer-weighted Magnetic Resonance Imaging.Current medical science · 2023Article
- CEST2022: Amide proton transfer-weighted MRI improves the diagnostic performance of multiparametric non-contrast-enhanced MRI techniques in patients with post-treatment high-grade gliomas.Magnetic resonance imaging · 2023Article
- Applications of chemical exchange saturation transfer magnetic resonance imaging in identifying genetic markers in gliomas.NMR in biomedicine · 2023Review
- Advanced MR Techniques for Preoperative Glioma Characterization: Part 2.Journal of magnetic resonance imaging : JMRI · 2023Review
- CEST-MRI for body oncologic imaging: are we there yet?NMR in biomedicine · 2023Review
- TowardBiosensors · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
objectivesTo comprehensively and noninvasively risk-stratify glioma grade, isocitrate dehydrogenase (IDH) genotype, and 1p/19q codeletion status using multi-contrast Z-spectral magnetic resonance imaging (MRI).
methodsOne hundred and thirteen patients with glioma were retrospectively included. Multiple contrasts contributing to Z-spectra, including direct saturation of water (DSW), semi-solid magnetization transfer contrast (MTC), amide proton transfer (APT) effect, aliphatic nuclear Overhauser effect, and the 2-ppm chemical exchange saturation transfer peak (CEST@2ppm), were fitted with five individual Lorentzian functions. Z-spectral contrasts were compared according to the three most important risk stratifications: tumor grade, IDH genotype, and 1p/19q codeletion status. We further investigated the differentiation of 1p/19q codeletion status within IDH mutant gliomas. The stratification performance of individual Z-spectral contrasts and their combination was quantified using receiver operating characteristic (ROC) analyses.
resultsDSW was significantly different within grade, IDH genotypes, and 1p/19q codeletion status. APT was significantly different with grade and IDH mutation, but not with 1p/19q subtypes. CEST@2ppm was only significantly different with 1p/19q codeletion subtypes. DSW and CEST@2ppm were the two Z-spectral contrasts able to differentiate 1p/19q codeletion subtypes within IDH mutant gliomas. For differentiating glioma grades using ROC analyses, DSW achieved the largest AUC. For differentiating IDH genotypes, DSW and APT achieved comparable AUCs. DSW was the best metric for differentiating 1p/19q codeletion status within all patients and within the IDH mutant patients. Combining all Z-spectral contrasts improved sensitivity and specificity for all risk stratifications.
conclusionsMulti-parametric Z-spectral MRI serves as a useful, comprehensive, and noninvasive imaging technique for glioma stratification in clinical patients. KEY POINTS: • Multiple contrasts contributing to Z-spectra were separately fitted with Lorentzian functions. • Z-spectral contrasts were compared within the three most important and common tumor risk stratifications for gliomas: tumor grade, IDH genotype, and 1p/19q codeletion status. • The stratification performance of individual Z-spectral contrasts and their combination was quantified using receiver operating characteristic analyses, which found Z-spectral MRI to be a useful and comprehensive imaging biomarker for glioma stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.